SENISCA Company Profile

Background

Overview:
SENISCA is a biotechnology company specializing in RNA-based therapeutics aimed at reversing cellular senescence to treat age-related diseases. Founded in 2020 as a spinout from the University of Exeter, SENISCA leverages over 15 years of research to develop interventions that rejuvenate aged cells by restoring their ability to regulate gene expression.

Mission and Vision:
SENISCA's mission is to develop innovative, effective pharmaceutical interventions that target the root causes of aging, enabling individuals to live healthier lives for longer. The company's vision encompasses delivering a new generation of oligonucleotide-based therapies to address both the diseases and aesthetic signs associated with aging.

Industry Significance:
By focusing on cellular senescence—a fundamental driver of age-related diseases—SENISCA positions itself at the forefront of the rapidly evolving field of senotherapeutics. Its proprietary technology offers potential treatments for a range of conditions, including those affecting the eyes, lungs, joints, and brain, addressing significant unmet medical needs.

Key Strategic Focus

Core Objectives:

Advance the development of RNA-based senotherapeutics targeting cellular senescence.

Transition from preclinical research to clinical-stage development.

Establish strategic partnerships to accelerate therapeutic commercialization.

Areas of Specialization:

Oligonucleotide-based interventions to reverse cellular aging.

Targeting RNA splicing dysregulation to modulate gene expression in senescent cells.

Key Technologies Utilized:

Proprietary RNA-based therapeutic platforms.

Advanced oligonucleotide design and delivery systems.

Primary Markets Targeted:

Pharmaceutical applications for age-related diseases.

Cosmeceutical products addressing aesthetic signs of aging.

Financials and Funding

Funding History:

March 2021: Secured £1.3 million in seed funding, exceeding the initial target of £950,000.

March 2024: Raised an additional £3.7 million, bringing total investor capital to £7.1 million.

Notable Investors:

Emerging Longevity Ventures

QantX

The R42 Group

Trend Investment Group

Apex Ventures

Lifespan Vision Ventures

Utilization of Capital:
Funds are allocated towards preclinical development of senotherapeutic programs, focusing on RNA splicing regulation to achieve cellular reprogramming and disease modification.

Pipeline Development

Key Pipeline Candidates:
SENISCA is developing a portfolio of proprietary therapeutics targeting cellular senescence through RNA splicing modulation.

Stages of Development:

Preclinical studies focusing on proof-of-concept and safety profiles.

Preparation for Investigational New Drug (IND) applications.

Target Conditions:

Age-related diseases affecting the eyes, lungs, joints, and brain.

Aesthetic applications addressing signs of skin aging.

Anticipated Milestones:

Completion of preclinical studies.

Initiation of clinical trials.

Establishment of strategic partnerships for commercialization.

Technological Platform and Innovation

Proprietary Technologies:

RNA-based therapeutic platforms designed to modulate gene expression in senescent cells.

Significant Scientific Methods:

Utilization of oligonucleotide-based approaches to restore RNA splicing function.

Development of assays to assess cellular rejuvenation and functional restoration.

Leadership Team

Sarah Cole, Ph.D.
Chief Executive Officer
Appointed CEO in November 2023, Dr. Cole brings extensive experience in biotechnology leadership and strategic development.

Lorna Harries, Ph.D.
Chief Scientific Officer & Co-Founder
A world leader in molecular and cellular biology, Dr. Harries has been instrumental in developing SENISCA's proprietary technology targeting cellular senescence.

Ben Lee, Ph.D.
Chief Technical Officer & Co-Founder
Dr. Lee oversees the technical development of SENISCA's therapeutic platforms, leveraging his expertise in RNA biology.

Kirsty Semple
Chief Operations Officer & Co-Founder
Ms. Semple manages operational strategies, ensuring alignment with SENISCA's mission and objectives.

Tim Edwards
Chair of the Board
Appointed in September 2024, Mr. Edwards brings over 30 years of leadership experience in the life sciences sector, guiding SENISCA towards clinical-stage development.

Leadership Changes

September 2024: Tim Edwards appointed as Chair of the Board, succeeding the late Dr. David Chiswell.

November 2023: Dr. Sarah Cole appointed as Chief Executive Officer.

Competitor Profile

Market Insights and Dynamics:
The senotherapeutics market is experiencing significant growth, driven by increasing interest in addressing the underlying causes of aging and age-related diseases. Advancements in RNA-based therapies and cellular reprogramming technologies are propelling the industry forward.

Competitor Analysis:

Alnylam Pharmaceuticals: Focuses on RNA interference (RNAi) therapeutics for genetic diseases.

Bitbrain: Specializes in neurotechnology solutions, including brain-computer interfaces.

Jellatech: Develops cell-based collagen and gelatin for various applications.

Opsin Biotherapeutics: Works on optogenetic therapies for vision restoration.

While these companies operate in related fields, SENISCA's unique focus on reversing cellular senescence through RNA splicing modulation distinguishes it within the competitive landscape.

Strategic Collaborations and Partnerships

SENISCA has secured investments from prominent venture capital firms specializing in longevity and biotechnology, including:

Emerging Longevity Ventures

QantX

The R42 Group

Trend Investment Group

Apex Ventures

Lifespan Vision Ventures

These partnerships provide not only financial support but also strategic guidance to advance SENISCA's therapeutic programs.

Operational Insights

Strategic Considerations:

Market Position: SENISCA's proprietary technology positions it as a leader in the senotherapeutics space, offering potential treatments for a range of age-related conditions.

Competitive Advantages: The company's focus on RNA splicing modulation and cellular reprogramming provides a novel approach to addressing aging at the cellular level.

Strategic Opportunities and Future Directions

Strategic Roadmap:

Advance preclinical programs to clinical trials.

Expand therapeutic applications to a broader range of age-related diseases.

Establish additional strategic partnerships for co-development and commercialization.

Opportunities for Expansion:

Development of cosmeceutical products targeting skin aging.

Exploration of combination therapies with existing treatments for synergistic effects.

Positioning for Future Objectives:
SENISCA's strong scientific foundation, experienced leadership, and strategic partnerships position the company to achieve its goal of delivering innovative senotherapeutics to the market, addressing significant unmet needs in age-related disease treatment.